Liquidia Corp (LQDA) · Oct 13, 2026 · Material agreement
PBM settlement — Payment due within three business days of the Global Settlement; amount redacted
Liquidia’s settlement agreement resolves a litigation-funding claim tied to United Therapeutics litigation, but the amount and cash impact remain undisclosed.
Liquidia is transitioning from a litigation-constrained biotech into a commercial PAH company built around YUTREPIA, while developing the follow-on L606 program. The broader United Therapeutics settlement announced alongside this filing keeps YUTREPIA available for PAH, but removes PH-ILD from the label after an adverse patent ruling and commits Liquidia to $380.7 million of total settlement-related payments across 2026 and 2027.
This agreement closes a separate litigation-finance claim rather than changing the core YUTREPIA settlement. Liquidia and Liquidia PAH agree to pay PBM an undisclosed amount within three business days after entering the Global Settlement with United Therapeutics. 〔0〕 The underlying funding and indemnification agreement remains fully effective until PBM is paid, after which PBM’s rights terminate. 〔1〕
The legal cleanup is real, but the economic read is incomplete. The agreement eliminates the risk of a separate PBM enforcement dispute once payment is made, yet the filing redacts the amount and therefore does not let investors judge the precise cash burden, accounting treatment, or how much of the broader settlement economics flows to PBM. Liquidia is jointly and severally liable with its subsidiary, and PBM can enforce either this agreement or the original indemnification agreement if payment is missed. 〔2〕 〔3〕
Because the direction was already telegraphed by the same-day Global Settlement, this is mostly detail rather than a fresh strategic surprise. The new information is the mechanics: PBM’s claim is being fixed and extinguished conditionally, but the undisclosed amount leaves an important piece of the settlement burden opaque. The next fuller financial read should come with Liquidia’s third-quarter 2026 update expected in November.
Bottom line: This filing removes one legal-finance overhang and makes the broader settlement executable, but it does not improve the economics of the deal on its own. Its significance is mainly confirmation and disclosure of payment mechanics, with the hidden PBM amount limiting transparency.
Third-quarter earnings call, November 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!